Acute lymphoblastic leukemiaNews & Research
15 curated articles for Acute lymphoblastic leukemia — FDA updates, peer-reviewed research, clinical-trial milestones, and sponsor press releases. Sorted newest-first.
- Pediatric blood & cancer Apr 22, 2026
Parent Quality of Life at Two Years Following Their Child's Completion of Acute Lymphoblastic Leukemia Treatment.
Parents of children treated for acute lymphoblastic leukemia (ALL) often experience significant caregiver burden and disruption to their well-being. While parent quality of life (QoL) during treatment is well characterized, little is known about outcomes during early survivorship. This study aimed t...
Why it matters: Recent peer-reviewed research on Acute lymphoblastic leukemia that may be relevant for patients and caregivers.
- Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics Apr 22, 2026
[Recent advances in individualized treatment for pediatric high-risk B-cell acute lymphoblastic leukemia].
B-cell acute lymphoblastic leukemia (B-ALL) is the most common hematologic malignancy in children. High-risk B-ALL, due to factors such as poor early treatment response and adverse genetic features, is prone to drug resistance and relapse, resulting in an unfavorable prognosis and posing a major cli...
Why it matters: Recent peer-reviewed research on Acute lymphoblastic leukemia that may be relevant for patients and caregivers.
- Discover oncology Apr 21, 2026
Investigating autophagy and miRNAs as therapeutic targets in leukemia.
Leukemia, characterized by the uncontrolled proliferation of abnormal white blood cells, encompasses several subtypes, including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), and chronic myeloid leukemia (CML). It presents a significant challen...
Why it matters: Recent peer-reviewed research on Acute lymphoblastic leukemia that may be relevant for patients and caregivers.
- Journal of medical virology Apr 21, 2026
Cytomegalovirus Reactivation During Therapy for Pediatric Acute Lymphoblastic Leukemia.
Cytomegalovirus (CMV) reactivation is a recognized complication after hematopoietic stem cell transplantation, but its relevance during conventional chemotherapy for pediatric acute lymphoblastic leukemia (ALL) is poorly defined, especially in CMV-prevalent regions. This retrospective cross-sectiona...
Why it matters: Recent peer-reviewed research on Acute lymphoblastic leukemia that may be relevant for patients and caregivers.
- Annals of hematology Apr 17, 2026
Identification of the Philadelphia-like subgroup in Turkish pediatric patients with acute lymphoblastic leukemia.
Ph-like ALL, a high-risk subgroup of B-cell ALL, is associated with a poor prognosis. The genetic diversity observed across different ethnicities underscores the importance of population-specific studies to gain a deeper understanding of its genetic drivers and clinical outcomes. This study aims to ...
Why it matters: Recent peer-reviewed research on Acute lymphoblastic leukemia that may be relevant for patients and caregivers.
- Discover oncology Apr 15, 2026
The combination therapy with venetoclax in therapeutic strategy of acute lymphoblastic leukemia.
Acute lymphoblastic leukemia (ALL) is characterized by the malignant transformation and proliferation of lymphoid progenitor cells in the bone marrow, blood, and extramedullary sites. Leukemic cells can develop drug resistance both before and after treatment, complicating disease management. Combina...
Why it matters: Recent peer-reviewed research on Acute lymphoblastic leukemia that may be relevant for patients and caregivers.
- Trends in cancer Apr 15, 2026
HSPC-like blasts in acute lymphoblastic leukemia: biology and therapeutic opportunities.
Stem cell-like blasts have been associated with hierarchical tumor-initiating potential and poor outcomes in myeloid leukemias. Previous studies using primary samples of acute lymphoblastic leukemia (ALL) have identified blasts that immunophenotypically and transcriptomically resemble hematopoietic ...
Why it matters: Recent peer-reviewed research on Acute lymphoblastic leukemia that may be relevant for patients and caregivers.
- NPJ precision oncology Apr 10, 2026
CD22-targeted immunotherapy for B-cell acute lymphoblastic leukemia progressing following CD19-targeted immunotherapy.
Patients progressing after CD19-targeted immunotherapy in r/r B-ALL experience poor outcomes. CD22-targeted therapies, including CD22 CAR-T cells and Inotuzumab Ozogamicin, show promise as alternatives, although data in those patients is limited. This study retrospectively analyzed 43 r/r B-ALL pati...
Why it matters: Recent peer-reviewed research on Acute lymphoblastic leukemia that may be relevant for patients and caregivers.
- Blood Mar 26, 2026
Comprehensive molecular and functional analysis of NUTM1-rearranged leukemia.
NUTM1 rearrangement defines a significant subset of B-cell acute lymphoblastic leukemia (B-ALL), particularly in infants lacking KMT2A rearrangements, yet its underlying molecular characteristics remain poorly understood. Here, we establish that NUTM1-rearranged (NUTM1-r) leukemia is a discrete enti...
Why it matters: Recent peer-reviewed research on Acute lymphoblastic leukemia that may be relevant for patients and caregivers.
- American journal of hematology Mar 17, 2026
The Care and Cure of the Leukemias in 2026.
It is an exciting era in leukemia owing to the development of novel targeted therapies and advances in genomics, pathophysiology, prognostication, and monitoring (e.g., highly sensitive measurable residual disease assays). Currently, most leukemias are effectively treated with immunotherapies (highl...
Why it matters: Recent peer-reviewed research on Acute lymphoblastic leukemia that may be relevant for patients and caregivers.
- Experimental oncology Mar 8, 2026
PHARMACOGENETIC MARKERS IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA THERAPY.
Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy. Despite major advances in therapy, the treatment of ALL remains a significant challenge. Therapeutic protocols are based on the use of combinations of chemotherapeutic drugs. While such combinations increase treatment effica...
Why it matters: Recent peer-reviewed research on Acute lymphoblastic leukemia that may be relevant for patients and caregivers.
- Molecular cancer therapeutics Mar 4, 2026
Targeting menin in T-lineage acute lymphoblastic leukemia.
T-lineage acute lymphoblastic leukemia (T-ALL) lacks effective targeted therapies, with poor outcomes in relapsed/refractory disease. HOXA-high T-ALL is biologically aggressive and often resistant to standard therapy. Menin inhibitors, recently approved for KMT2A-rearranged leukemias, may be effecti...
Why it matters: Recent peer-reviewed research on Acute lymphoblastic leukemia that may be relevant for patients and caregivers.
- Blood Feb 19, 2026
Age-adapted chemotherapy and MRD-oriented transplant for Ph-negative acute lymphoblastic leukemia: the GRAALL-2014 trial.
The Group for Research in Adult Acute Lymphoblastic Leukemia (GRAALL)-2014 trial evaluated an intensive, age-adapted protocol for adults aged 18 to 59 years with Philadelphia chromosome negative acute lymphoblastic leukemia. The trial was motivated by findings from the previous GRAALL-2005 study, wh...
Why it matters: Recent peer-reviewed research on Acute lymphoblastic leukemia that may be relevant for patients and caregivers.
- The American journal of clinical nutrition Feb 4, 2026
Undernutrition or obesity: relationship with long-term survival in children with acute lymphoblastic leukemia in an upper-middle income country: a multicenter cohort study.
Long-term survival rates for children with acute lymphoblastic leukemia (ALL) have not improved in some countries, with undernutrition and obesity identified as potential contributing factors. To evaluate the relationship between undernutrition and obesity in long-term survival in Mexican children w...
Why it matters: Recent peer-reviewed research on Acute lymphoblastic leukemia that may be relevant for patients and caregivers.
- Blood advances Jan 16, 2026
Ectopic expression of BEX genes in T-cell acute lymphoblastic leukemia.
T-cell acute lymphoblastic leukemia (T-ALL) is a malignant proliferation of T-cell progenitors originating in the thymus. T-ALL is a heterogenous disease involving the dysregulation of various oncogenes/tumor-suppressor (TS) genes. Loss of the TS gene phosphatase and TENsin homolog (PTEN) is a recur...
Why it matters: Recent peer-reviewed research on Acute lymphoblastic leukemia that may be relevant for patients and caregivers.
More on Acute lymphoblastic leukemia
Articles aggregated from peer-reviewed journals (PubMed), sponsor press releases, SEC 8-K filings, and FDA announcements. Original-source links are preserved on each article page. Editorial tags (Breaking / Notable / Update) reflect UniteRare's curation-time priority assessment.